Innovation and R&D Pipeline
A diversified portfolio and differentiated design, featuring an innovative cell therapy pipeline covering hematologic malignancies, solid tumors, and autoimmune diseases
Program
Target
Indication
Preclinical
IIT
IND
Phase I
Pivotal Trial
Regulatory Review
Approved
Collaboration
Autologous CAR-T Platform
Relma-cel
CD19
LBCL / FL / MCL(3L+)
Bristol Myers Squibb
Relma-cel
CD19
LBCL (2L)
Relma-cel
CD19
SLE
Relma-cel
CD19
SSc
JWCAR201
CD19/20
NHL
JWCAR201
CD19/20
SLE / LN
JWCAR239
CD19/CD20 (Dual-target, Dual-armored)
LBCL
JWCAR129
BCMA
MM
Bristol Myers Squibb
JWCAR031
DLL3
SCLC
Autologous TCR-T Platform
JWTCR001
MAGE-A4
Solid Tumors
Regeneron
In vivo CAR-T Platform
JWCAR306
CD19/20
NHL
JWCAR308
Undisclosed
SCLC
Autologous CAR-T Platform
Relma-cel
Collaboration
Bristol Myers Squibb
Preclinical
IIT
IND
Phase I
Pivotal Trial
Regulatory Review
Approved
Relma-cel
Preclinical
IIT
IND
Phase I
Pivotal Trial
Regulatory Review
Approved
Relma-cel
Preclinical
IIT
IND
Phase I
Pivotal Trial
Regulatory Review
Approved
Relma-cel
Preclinical
IIT
IND
Phase I
Pivotal Trial
Regulatory Review
Approved
JWCAR201
Preclinical
IIT
IND
Phase I
Pivotal Trial
Regulatory Review
Approved
JWCAR201
Preclinical
IIT
IND
Phase I
Pivotal Trial
Regulatory Review
Approved
JWCAR239
Preclinical
IIT
IND
Phase I
Pivotal Trial
Regulatory Review
Approved
JWCAR129
Collaboration
Bristol Myers Squibb
Preclinical
IIT
IND
Phase I
Pivotal Trial
Regulatory Review
Approved
JWCAR031
Preclinical
IIT
IND
Phase I
Pivotal Trial
Regulatory Review
Approved
Autologous TCR-T Platform
JWTCR001
Collaboration
Regeneron
Preclinical
IIT
IND
Phase I
Pivotal Trial
Regulatory Review
Approved
In vivo CAR-T Platform
JWCAR306
Preclinical
IIT
IND
Phase I
Pivotal Trial
Regulatory Review
Approved
JWCAR308
Preclinical
IIT
IND
Phase I
Pivotal Trial
Regulatory Review
Approved